Based in the heart of Europe, high capacity and great flexibility for clients is ensured by more than 180 clinical pharmacology beds amongst 3 facilities: Kiel, Mönchengladbach and Mannheim. Our 28 bed unit at Kiel is ready and equipped to handle clinical trials in highly sought after special populations such as those with renal and hepatic impairment.

Our supporting service centres have global reach from Grünstadt: Bioanalytics, Biomarker Capability, Clinical Data Management (CDM), Biostatistics, Medical Writing and Clinical Trial Supply Management (CTSM).

The intention behind merging three CROs was to concentrate more clinical pharmacology experience, more capabilities and capacity to conduct your study projects.

All CRS member companies are located in metropolitan areas. Accessibility of several million people was one of the reasons for the merger giving the chance to facilitate recruitment of either patients, healthy volunteers or symptom bearing subjects.

With share capital of € 972,600.00, the shareholders are LTS Lohmann Therapie-Systeme AG, Andernach, (represented by Chairman, Dr. H. Rainer Hoffmann), 76%; Dr. Torben Thomsen, Andernach, 14.75%; Dr. Atef Halabi, Kiel, 6%; Prof. Harald Darius, Berlin, 3.25%.